Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 321

1.

Pneumonia in Patients with Chronic Obstructive Pulmonary Disease.

Restrepo MI, Sibila O, Anzueto A.

Tuberc Respir Dis (Seoul). 2018 Jul;81(3):187-197. doi: 10.4046/trd.2018.0030. Review.

2.

Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study.

Anzueto AR, Kostikas K, Mezzi K, Shen S, Larbig M, Patalano F, Fogel R, Banerji D, Wedzicha JA.

Respir Res. 2018 Jun 20;19(1):121. doi: 10.1186/s12931-018-0830-z.

3.

Chronic Obstructive Pulmonary Disease Exacerbations: a Need for Action.

Anzueto A, Miravitlles M.

Am J Med. 2018 May 16. pii: S0002-9343(18)30416-9. doi: 10.1016/j.amjmed.2018.05.003. [Epub ahead of print]

PMID:
29777660
4.

Determinants of Response to Roflumilast in Severe COPD: Pooled Analysis of Two Randomized Trials.

Martinez FJ, Rabe KF, Calverley PMA, Fabbri LM, Sethi S, Pizzichini E, McIvor A, Anzueto A, Alagappan VKT, Siddiqui S, Reisner C, Zetterstrand S, Román J, Purkayastha D, Bagul N, Rennard SI.

Am J Respir Crit Care Med. 2018 May 15. doi: 10.1164/rccm.201712-2493OC. [Epub ahead of print]

PMID:
29763572
5.

Treatment of exacerbations as a predictor of subsequent outcomes in patients with COPD.

Calverley PM, Anzueto AR, Dusser D, Mueller A, Metzdorf N, Wise RA.

Int J Chron Obstruct Pulmon Dis. 2018 Apr 23;13:1297-1308. doi: 10.2147/COPD.S153631. eCollection 2018.

6.

Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial.

Calverley PMA, Anzueto AR, Carter K, Grönke L, Hallmann C, Jenkins C, Wedzicha J, Rabe KF.

Lancet Respir Med. 2018 May;6(5):337-344. doi: 10.1016/S2213-2600(18)30102-4. Epub 2018 Apr 5.

PMID:
29605624
7.

Considerations for the Correct Diagnosis of COPD and Its Management With Bronchodilators.

Anzueto A, Miravitlles M.

Chest. 2018 Mar 8. pii: S0012-3692(18)30390-8. doi: 10.1016/j.chest.2018.02.023. [Epub ahead of print]

8.

Seasonal variations in exacerbations and deaths in patients with COPD during the TIOSPIR® trial.

Wise RA, Calverley PM, Carter K, Clerisme-Beaty E, Metzdorf N, Anzueto A.

Int J Chron Obstruct Pulmon Dis. 2018 Feb 14;13:605-616. doi: 10.2147/COPD.S148393. eCollection 2018.

9.

Pulmonary rehabilitation for patients with COPD during and after an exacerbation-related hospitalisation: back to the future?

Wilson KC, Krishnan JA, Sliwinski P, Criner GJ, Miravitlles M, Hurst JR, Calverley PMA, Albert RK, Rigau D, Tonia T, Vestbo J, Papi A, Rabe KF, Anzueto A, Wedzicha JA.

Eur Respir J. 2018 Jan 11;51(1). pii: 1702577. doi: 10.1183/13993003.02577-2017. Print 2018 Jan. No abstract available.

PMID:
29326324
10.

Demographic Characteristics and Clinical Outcomes in Patients from Latin America Versus the Rest of the World: A TIOSPIR® Post-Hoc Analysis.

Anzueto A, Calverley PMA, Mueller A, Metzdorf N, Haensel M, Jardim JR, Pizzichini E, Giraldo H, Ramirez-Venegas A, Giugno ER.

Arch Bronconeumol. 2018 Mar;54(3):140-148. doi: 10.1016/j.arbres.2017.11.010. Epub 2018 Jan 6. English, Spanish.

11.

The Role of Fixed-Dose Dual Bronchodilator Therapy in Treating COPD.

Anzueto A, Miravitlles M.

Am J Med. 2018 Jun;131(6):608-622. doi: 10.1016/j.amjmed.2017.12.018. Epub 2018 Jan 3. Review.

12.

The Association Between Major Depressive Disorder and Outcomes in Older Veterans Hospitalized With Pneumonia.

DeWaters AL, Chansard M, Anzueto A, Pugh MJ, Mortensen EM.

Am J Med Sci. 2018 Jan;355(1):21-26. doi: 10.1016/j.amjms.2017.08.015. Epub 2017 Nov 20.

PMID:
29289257
13.

Determinants of exacerbation risk in patients with COPD in the TIOSPIR study.

Calverley PM, Tetzlaff K, Dusser D, Wise RA, Mueller A, Metzdorf N, Anzueto A.

Int J Chron Obstruct Pulmon Dis. 2017 Nov 29;12:3391-3405. doi: 10.2147/COPD.S145814. eCollection 2017.

14.

Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline.

Wedzicha JA, Calverley PMA, Albert RK, Anzueto A, Criner GJ, Hurst JR, Miravitlles M, Papi A, Rabe KF, Rigau D, Sliwinski P, Tonia T, Vestbo J, Wilson KC, Krishnan JA.

Eur Respir J. 2017 Sep 9;50(3). pii: 1602265. doi: 10.1183/13993003.02265-2016. Print 2017 Sep.

PMID:
28889106
15.

Susceptibility to exacerbation in COPD.

Hurst JR, Anzueto A, Vestbo J.

Lancet Respir Med. 2017 Sep;5(9):e29. doi: 10.1016/S2213-2600(17)30307-7. No abstract available.

PMID:
28853400
16.

Guiding Principles for the Use of Nebulized Long-Acting Beta2-Agonists in Patients with COPD: An Expert Panel Consensus.

Wise RA, Acevedo RA, Anzueto AR, Hanania NA, Martinez FJ, Ohar JA, Tashkin DP.

Chronic Obstr Pulm Dis. 2016 Nov 15;4(1):7-20. doi: 10.15326/jcopdf.4.1.2016.0141.

17.

Blood eosinophil count and exacerbation risk in patients with COPD.

Kerkhof M, Sonnappa S, Postma DS, Brusselle G, Agustí A, Anzueto A, Jones R, Papi A, Pavord I, Pizzichini E, Popov T, Roche N, Ryan D, Thomas M, Vogelmeier C, Chisholm A, Freeman D, Bafadhel M, Hillyer EV, Price DB.

Eur Respir J. 2017 Jul 20;50(1). pii: 1700761. doi: 10.1183/13993003.00761-2017. Print 2017 Jul. No abstract available.

PMID:
28729477
18.

Risk Factors for Noninvasive Ventilation Failure in Critically Ill Subjects With Confirmed Influenza Infection.

Rodríguez A, Ferri C, Martin-Loeches I, Díaz E, Masclans JR, Gordo F, Sole-Violán J, Bodí M, Avilés-Jurado FX, Trefler S, Magret M, Moreno G, Reyes LF, Marin-Corral J, Yebenes JC, Esteban A, Anzueto A, Aliberti S, Restrepo MI; Grupo Español de Trabajo Gripe A Grave (GETGAG)/Sociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias (SEMICYUC) Working Group; 2009-2015 H1N1 SEMICYUC Working Group investigators.

Respir Care. 2017 Oct;62(10):1307-1315. doi: 10.4187/respcare.05481. Epub 2017 Jul 11.

PMID:
28698265
19.

High endocan levels are associated with the need for mechanical ventilation among patients with severe sepsis.

Mangat M, Amalakuhan B, Habib S, Reyes LF, Hinojosa CA, Rodriguez AH, Soni NJ, Anzueto A, Levine SM, Peters JI, Aliberti S, Sibila O, Rello J, Witzenrath M, Waterer GW, Martin-Loeches I, Blanquer J, Sanz F, Marcos PJ, Solé-Violán J, Chalmers JD, Feldman C, Wunderink RG, Cruz CSD, Orihuela CJ, Restrepo MI.

Eur Respir J. 2017 Jul 5;50(1). pii: 1700013. doi: 10.1183/13993003.00013-2017. Print 2017 Jul. No abstract available.

PMID:
28679609
20.

Erratum to "Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary" [Arch Bronconeumol. 2017;53:128-49].

Vogelmeier CF, Criner GJ, Martínez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DMG, Varela MVL, Nishimura M, Roche N, Rodríguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agustí A.

Arch Bronconeumol. 2017 Jul;53(7):411-412. doi: 10.1016/j.arbres.2017.06.001. English, Spanish. No abstract available.

21.

Chronic Respiratory Infection in Patients with Chronic Obstructive Pulmonary Disease: What Is the Role of Antibiotics?

Miravitlles M, Anzueto A.

Int J Mol Sci. 2017 Jun 23;18(7). pii: E1344. doi: 10.3390/ijms18071344. Review.

22.

Optimizing bronchodilation in the prevention of COPD exacerbations.

Miravitlles M, Anzueto A, Jardim JR.

Respir Res. 2017 Jun 20;18(1):125. doi: 10.1186/s12931-017-0601-2. Review.

23.

Severe Pneumococcal Pneumonia Causes Acute Cardiac Toxicity and Subsequent Cardiac Remodeling.

Reyes LF, Restrepo MI, Hinojosa CA, Soni NJ, Anzueto A, Babu BL, Gonzalez-Juarbe N, Rodriguez AH, Jimenez A, Chalmers JD, Aliberti S, Sibila O, Winter VT, Coalson JJ, Giavedoni LD, Dela Cruz CS, Waterer GW, Witzenrath M, Suttorp N, Dube PH, Orihuela CJ.

Am J Respir Crit Care Med. 2017 Sep 1;196(5):609-620. doi: 10.1164/rccm.201701-0104OC.

PMID:
28614669
24.

The effect of COPD severity and study duration on exacerbation outcome in randomized controlled trials.

Eriksson G, Calverley PM, Jenkins CR, Anzueto AR, Make BJ, Lindberg M, Fagerås M, Postma DS.

Int J Chron Obstruct Pulmon Dis. 2017 May 15;12:1457-1468. doi: 10.2147/COPD.S130713. eCollection 2017.

25.

The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD.

Anzueto AR, Vogelmeier CF, Kostikas K, Mezzi K, Fucile S, Bader G, Shen S, Banerji D, Fogel R.

Int J Chron Obstruct Pulmon Dis. 2017 May 4;12:1325-1337. doi: 10.2147/COPD.S133307. eCollection 2017.

26.

Effectiveness and safety of mycophenolate mofetil in idiopathic pulmonary fibrosis.

Nambiar AM, Anzueto AR, Peters JI.

PLoS One. 2017 Apr 25;12(4):e0176312. doi: 10.1371/journal.pone.0176312. eCollection 2017.

27.

Acute Kidney Injury in Mechanically Ventilated Patients: The Risk Factor Profile Depends on the Timing of Aki Onset.

Lombardi R, Nin N, Peñuelas O, Ferreiro A, Rios F, Marin MC, Raymondos K, Lorente JA, Koh Y, Hurtado J, Gonzalez M, Abroug F, Jibaja M, Arabi Y, Moreno R, Matamis D, Anzueto A, Esteban A; VENTILA Group.

Shock. 2017 Oct;48(4):411-417. doi: 10.1097/SHK.0000000000000871.

PMID:
28379920
28.

LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis.

Rodrigo GJ, Price D, Anzueto A, Singh D, Altman P, Bader G, Patalano F, Fogel R, Kostikas K.

Int J Chron Obstruct Pulmon Dis. 2017 Mar 17;12:907-922. doi: 10.2147/COPD.S130482. eCollection 2017. Review.

29.

Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline.

Wedzicha JA Ers Co-Chair, Miravitlles M, Hurst JR, Calverley PM, Albert RK, Anzueto A, Criner GJ, Papi A, Rabe KF, Rigau D, Sliwinski P, Tonia T, Vestbo J, Wilson KC, Krishnan JA Ats Co-Chair.

Eur Respir J. 2017 Mar 15;49(3). pii: 1600791. doi: 10.1183/13993003.00791-2016. Print 2017 Mar.

PMID:
28298398
30.

Pathophysiology of dyspnea in COPD.

Anzueto A, Miravitlles M.

Postgrad Med. 2017 Apr;129(3):366-374. doi: 10.1080/00325481.2017.1301190. Epub 2017 Mar 17. Review.

PMID:
28277858
31.

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.

Vogelmeier CF, Criner GJ, Martínez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DM, López Varela MV, Nishimura M, Roche N, Rodríguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agustí A.

Arch Bronconeumol. 2017 Mar;53(3):128-149. doi: 10.1016/j.arbres.2017.02.001. Epub 2017 Mar 6. English, Spanish. Erratum in: Arch Bronconeumol. 2017 Jul;53(7):411-412.

32.

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.

Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DM, López Varela MV, Nishimura M, Roche N, Rodriguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agusti A.

Eur Respir J. 2017 Mar 6;49(3). pii: 1700214. doi: 10.1183/13993003.00214-2017. Print 2017 Mar. Erratum in: Eur Respir J. 2017 Jun 22;49(6):.

PMID:
28182564
33.

A new two-step algorithm for the treatment of COPD.

Miravitlles M, Anzueto A.

Eur Respir J. 2017 Feb 8;49(2). pii: 1602200. doi: 10.1183/13993003.02200-2016. Print 2017 Feb. No abstract available.

PMID:
28179443
34.

Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.

Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DM, López Varela MV, Nishimura M, Roche N, Rodriguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agusti A.

Respirology. 2017 Apr;22(3):575-601. doi: 10.1111/resp.13012. Epub 2017 Mar 7.

35.

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary.

Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DM, López Varela MV, Nishimura M, Roche N, Rodriguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agustí A.

Am J Respir Crit Care Med. 2017 Mar 1;195(5):557-582. doi: 10.1164/rccm.201701-0218PP.

36.

Severe hypercapnia and outcome of mechanically ventilated patients with moderate or severe acute respiratory distress syndrome.

Nin N, Muriel A, Peñuelas O, Brochard L, Lorente JA, Ferguson ND, Raymondos K, Ríos F, Violi DA, Thille AW, González M, Villagomez AJ, Hurtado J, Davies AR, Du B, Maggiore SM, Soto L, D'Empaire G, Matamis D, Abroug F, Moreno RP, Soares MA, Arabi Y, Sandi F, Jibaja M, Amin P, Koh Y, Kuiper MA, Bülow HH, Zeggwagh AA, Anzueto A, Sznajder JI, Esteban A; VENTILA Group.

Intensive Care Med. 2017 Feb;43(2):200-208. doi: 10.1007/s00134-016-4611-1. Epub 2017 Jan 20.

37.

Early efficacy of budesonide/formoterol in patients with moderate-to-very-severe COPD.

Calverley PM, Eriksson G, Jenkins CR, Anzueto AR, Make BJ, Persson A, Fagerås M, Postma DS.

Int J Chron Obstruct Pulmon Dis. 2016 Dec 19;12:13-25. doi: 10.2147/COPD.S114209. eCollection 2017.

38.

Complication of Community-Acquired Pneumonia (Including Cardiac Complications).

Restrepo MI, Reyes LF, Anzueto A.

Semin Respir Crit Care Med. 2016 Dec;37(6):897-904. Epub 2016 Dec 13. Review.

PMID:
27960213
39.

Association between ventilatory settings and development of acute respiratory distress syndrome in mechanically ventilated patients due to brain injury.

Tejerina E, Pelosi P, Muriel A, Peñuelas O, Sutherasan Y, Frutos-Vivar F, Nin N, Davies AR, Rios F, Violi DA, Raymondos K, Hurtado J, González M, Du B, Amin P, Maggiore SM, Thille AW, Soares MA, Jibaja M, Villagomez AJ, Kuiper MA, Koh Y, Moreno RP, Zeggwagh AA, Matamis D, Anzueto A, Ferguson ND, Esteban A; for VENTILA group.

J Crit Care. 2017 Apr;38:341-345. doi: 10.1016/j.jcrc.2016.11.010. Epub 2016 Nov 18.

PMID:
27914908
40.

A Non-Human Primate Model of Severe Pneumococcal Pneumonia.

Reyes LF, Restrepo MI, Hinojosa CA, Soni NJ, Shenoy AT, Gilley RP, Gonzalez-Juarbe N, Noda JR, Winter VT, de la Garza MA, Shade RE, Coalson JJ, Giavedoni LD, Anzueto A, Orihuela CJ.

PLoS One. 2016 Nov 17;11(11):e0166092. doi: 10.1371/journal.pone.0166092. eCollection 2016.

41.

Health care-associated pneumonia in the intensive care unit: Guideline-concordant antibiotics and outcomes.

Attridge RT, Frei CR, Pugh MJ, Lawson KA, Ryan L, Anzueto A, Metersky ML, Restrepo MI, Mortensen EM.

J Crit Care. 2016 Dec;36:265-271. doi: 10.1016/j.jcrc.2016.08.004. Epub 2016 Aug 11.

42.
43.

Endothelial adhesion molecules and multiple organ failure in patients with severe sepsis.

Amalakuhan B, Habib SA, Mangat M, Reyes LF, Rodriguez AH, Hinojosa CA, Soni NJ, Gilley RP, Bustamante CA, Anzueto A, Levine SM, Peters JI, Aliberti S, Sibila O, Chalmers JD, Torres A, Waterer GW, Martin-Loeches I, Bordon J, Blanquer J, Sanz F, Marcos PJ, Rello J, Ramirez J, Solé-Violán J, Luna CM, Feldman C, Witzenrath M, Wunderink RG, Stolz D, Wiemken TL, Shindo Y, Dela Cruz CS, Orihuela CJ, Restrepo MI.

Cytokine. 2016 Dec;88:267-273. doi: 10.1016/j.cyto.2016.08.028. Epub 2016 Oct 1.

44.

Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial.

Martinez FJ, Rabe KF, Sethi S, Pizzichini E, McIvor A, Anzueto A, Alagappan VK, Siddiqui S, Rekeda L, Miller CJ, Zetterstrand S, Reisner C, Rennard SI.

Am J Respir Crit Care Med. 2016 Sep 1;194(5):559-67. doi: 10.1164/rccm.201607-1349OC.

PMID:
27585384
45.

Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.

Rennard SI, Martinez FJ, Rabe KF, Sethi S, Pizzichini E, McIvor A, Siddiqui S, Anzueto A, Zhu H.

Int J Chron Obstruct Pulmon Dis. 2016 Aug 17;11:1921-8. doi: 10.2147/COPD.S109661. eCollection 2016.

46.

Acute Exacerbations and Lung Function Loss in Smokers with and without Chronic Obstructive Pulmonary Disease.

Dransfield MT, Kunisaki KM, Strand MJ, Anzueto A, Bhatt SP, Bowler RP, Criner GJ, Curtis JL, Hanania NA, Nath H, Putcha N, Roark SE, Wan ES, Washko GR, Wells JM, Wendt CH, Make BJ; COPDGene Investigators.

Am J Respir Crit Care Med. 2017 Feb 1;195(3):324-330. doi: 10.1164/rccm.201605-1014OC.

47.

TIOtropium Safety and Performance In Respimat® (TIOSPIRTM ): Analysis of Asian cohort of COPD patients.

Zhong N, Moon HS, Lee KH, Mahayiddin AA, Boonsawat W, Isidro MG, Bai C, Mueller A, Metzdorf N, Anzueto A.

Respirology. 2016 Nov;21(8):1397-1403. doi: 10.1111/resp.12856. Epub 2016 Aug 4.

48.

Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis.

Pavord ID, Lettis S, Anzueto A, Barnes N.

Lancet Respir Med. 2016 Sep;4(9):731-741. doi: 10.1016/S2213-2600(16)30148-5. Epub 2016 Jul 23.

PMID:
27460163
49.

Tiotropium safety in 'real-world' populations: Response to Schmiedl, et al. in the British Journal of Clinical Pharmacology.

Wise R, Anzueto A, Dahl R, Dusser D, Calverley P.

Br J Clin Pharmacol. 2016 Aug;82(2):562-3. doi: 10.1111/bcp.12972. Epub 2016 May 19. No abstract available.

50.

Persistent and Newly Developed Chronic Bronchitis Are Associated with Worse Outcomes in Chronic Obstructive Pulmonary Disease.

Kim V, Zhao H, Boriek AM, Anzueto A, Soler X, Bhatt SP, Rennard SI, Wise R, Comellas A, Ramsdell JW, Kinney GL, Han MK, Martinez CH, Yen A, Black-Shinn J, Porszasz J, Criner GJ, Hanania NA, Sharafkhaneh A, Crapo JD, Make BJ, Silverman EK, Curtis JL; COPDGene Investigators.

Ann Am Thorac Soc. 2016 Jul;13(7):1016-25. doi: 10.1513/AnnalsATS.201512-800OC.

Supplemental Content

Loading ...
Support Center